Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

The researchers examined the influence of hANP infusion on cardiac and renal function in patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG).

Who Took Part

The abstract describes 133 patients taking part.

The age groups tagged for this paper are older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

As a double-blind ANP (Atrial Natriuretic Peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Coronary Artery Bypass, Creatinine, Glomerular Filtration Rate, Postoperative Complications, Stroke Volume and Ventricular Dysfunction, Left.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 133 patients.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Journal of the American College of Cardiology), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.